Information Provided By:
Fly News Breaks for September 21, 2017
Sep 21, 2017 | 06:03 EDT
Raymond James analyst Laura Chico downgraded BioGen to Market Perform following the latest MS survey feedback that continues to show headwinds to the franchise. The doctors surveyed anticipate Roche's Ocrevus market share will more than double from current 3% to 7.7% by Q1 2018 as many view it as a safer, more efficacious alternative versus Tysabri. The analyst said MS headwinds are not new but his derived fair value for Biogen of $329 leaves little upside to where shares currently trade.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.